BioXcel Therapeutics, Inc. — Director's Dealing 2019

Jun 20, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2019-05-23

Reporting Person: Votruba Michal (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-05-23	Stock Option (Right to Buy)	$10.04	A	4700	Acquired	2029-05-23	Common Stock (4700)	Direct
2019-05-23	Stock Option (Right to Buy)	$10.04	J	4700	Disposed	2029-05-23	Common Stock (4700)	Direct

Footnotes

F1: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. acting in respect of its sub-fund RSJ Gradus podfund ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person does not beneficially own any of the securities reported herein.

F2: The option will vest in full and become exercisable on the first anniversary of the grant date.